Anika Therapeutics (ANIK)
(Delayed Data from NSDQ)
$25.59 USD
+0.77 (3.10%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $25.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Balance Sheet
Fiscal Year End for Anika Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 73 | 86 | 94 | 98 | 185 |
Receivables | 36 | 35 | 30 | 24 | 23 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 46 | 40 | 36 | 46 | 22 |
Other Current Assets | 8 | 9 | 8 | 9 | 4 |
Total Current Assets | 163 | 170 | 169 | 177 | 234 |
Net Property & Equipment | 46 | 48 | 48 | 51 | 51 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 1 | 1 | 0 | 0 | 0 |
Intangibles | 12 | 82 | 90 | 100 | 15 |
Deposits & Other Assets | 19 | 17 | 20 | 15 | 7 |
Total Assets | 271 | 349 | 348 | 366 | 331 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 9 | 8 | 9 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 21 | 19 | 18 | 15 | 12 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 4 | 13 | 0 |
Total Current Liabilities | 31 | 28 | 30 | 37 | 16 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 6 | 10 | 12 | 4 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 1 | 24 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 58 | 64 | 60 | 93 | 42 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 90 | 81 | 67 | 55 | 49 |
Retained Earnings | 128 | 211 | 226 | 221 | 245 |
Other Equity | -6 | -6 | -6 | -5 | -6 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 212 | 286 | 287 | 272 | 288 |
Total Liabilities & Shareholder's Equity | 271 | 349 | 348 | 366 | 331 |
Total Common Equity | 212 | 286 | 287 | 272 | 288 |
Shares Outstanding | 14.60 | 14.60 | 14.40 | 14.20 | 14.20 |
Book Value Per Share | 14.54 | 19.56 | 19.94 | 19.18 | 20.31 |
Fiscal Year End for Anika Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 63 | 69 | 73 | 71 | 65 |
Receivables | 34 | 32 | 36 | 35 | 37 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 51 | 49 | 46 | 44 | 43 |
Other Current Assets | 7 | 9 | 8 | 8 | 8 |
Total Current Assets | 155 | 159 | 163 | 157 | 152 |
Net Property & Equipment | 48 | 46 | 46 | 46 | 48 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 1 | 1 | 1 | 1 | 2 |
Intangibles | 11 | 12 | 12 | 76 | 78 |
Deposits & Other Assets | 20 | 18 | 19 | 19 | 19 |
Total Assets | 263 | 264 | 271 | 328 | 329 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 10 | 10 | 8 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 16 | 18 | 21 | 20 | 16 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 26 | 28 | 31 | 28 | 23 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 2 | 3 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 52 | 55 | 58 | 58 | 55 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 93 | 91 | 90 | 86 | 82 |
Retained Earnings | 123 | 124 | 128 | 191 | 198 |
Other Equity | -6 | -6 | -6 | -7 | -6 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 210 | 209 | 212 | 270 | 274 |
Total Liabilities & Shareholder's Equity | 263 | 264 | 271 | 328 | 329 |
Total Common Equity | 210 | 209 | 212 | 270 | 274 |
Shares Outstanding | 14.80 | 14.80 | 14.60 | 14.60 | 14.70 |
Book Value Per Share | 14.21 | 14.09 | 14.54 | 18.53 | 18.64 |